Lexicon Pharmaceuticals
LXRX
102 hedge funds and large institutions have $1.12B invested in Lexicon Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 37 increasing their positions, 27 reducing their positions, and 8 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 27
10% more capital invested
Capital invested by funds: $1.02B → $1.12B (+$100M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
1% less funds holding
Funds holding: 103 → 102 (-1)
Top Buyers
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.62M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$3.64M |
| 3 |
Morgan Stanley
New York
|
-$2.88M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$1.57M |
| 5 |
JP Morgan Chase
New York
|
-$1.47M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCM
101
Highlander Capital Management
Short Hills,
New Jersey
| $714 | – | – | – |
|
102
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $431 | -$21.3K | -1,270 | -5% |
|
|
103
Allianz Asset Management
Munich,
Germany
| – | -$3.64M | -239,700 | Closed |
|
|
HHMI
104
Howard Hughes Medical Institute
Chevy Chase,
Maryland
| – | -$296K | -19,504 | Closed |
|
|
UR
105
USCA RIA
Houston,
Texas
| – | -$87K | -5,714 | Closed |
|
|
V
106
Veritable
Wilmington,
Delaware
| – | -$43K | -2,857 | Closed |
|
|
CA
107
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
| – | -$34K | -2,257 | Closed |
|
|
SBCM
108
Silver Bridge Capital Management
Boston,
Massachusetts
| – | -$22K | -1,429 | Closed |
|
109
Creative Planning
Overland Park,
Kansas
| – | -$2K | -143 | Closed |
|
LXRX Hedge Fund Activity: Q3 2013 in Review
102 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q3 2013, worth a combined $1.12B — up 9.9% from $1.02B a quarter earlier.
Fund positioning in LXRX was balanced in Q3 2013: 8 funds opened new positions, 8 closed out, 37 added to existing stakes and 27 trimmed.
The largest buyer was UBS AM, adding an estimated $11.9M. The largest seller was Vanguard Group, cutting an estimated $4.62M.
- 102 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q3 2013, down from 103 in Q2 2013.
- Funds reported $1.12B of Lexicon Pharmaceuticals stock for Q3 2013, up 9.9% quarter-over-quarter.
- 8 funds opened new Lexicon Pharmaceuticals positions in Q3 2013 and 8 closed out, a net change of 0 holders.
- The largest Lexicon Pharmaceuticals buyer in Q3 2013 was UBS AM, an estimated $11.9M added.
- The largest Lexicon Pharmaceuticals seller in Q3 2013 was Vanguard Group, an estimated $4.62M sold.
Based on aggregated 13F filings for Q3 2013.